Corcept's Relacorilant Shows Long-Term Cardiometabolic Benefits In Hypercortisolism Patients

(RTTNews) - Corcept Therapeutics Inc. (CORT), Monday announced data from its Phase 3 long-term extension study, evaluating relacorilant in patients with endogenous hypercortisolism, which is caused by excessive activity of the hormone cortisol.

The findings showed that patients treated with relacorilant experienced clinically meaningful and durable cardiometabolic improvements. It was well-tolerated, with a treatment duration of up to six years.

Moreover, the participants experienced improvement in blood pressure while maintaining response in other cardiometabolic measures, such as glycemic control and body weight.

Currently, Corcept's stock is trading at $54.95, down 0.81 percent on the Nasdaq.